FIELD: medicine, pharmaceutics, urology.
SUBSTANCE: the present innovation deals with pharmaceutical composition, its application and methods for treating the states being characterized with unfavourable oxalatic absorption out of gastrointestinal tract due to introducing such a composition that includes, at lest, one intoxic salt of rare-earth metal ion, not obligatory in hydratized form, for example, lanthanum [La]2[CO3]3·cH20. The composition mentioned should be introduced into gastrointestinal tract at the quantity being efficient for treating the state that is characterized with unfavourable oxalatic absorption out of gastrointestinal tract. The innovation provides the binding of insoluble oxalates despite pH level due to avoiding their entering the urinary system.
EFFECT: higher efficiency.
21 cl, 6 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORAL COMPOSITION FOR PHOSPHOROUS COMPOUNDS ABSORPTION | 2005 |
|
RU2392926C2 |
| NICOTINAMIDE FOR TREATING DISLIPIDEMIA | 2018 |
|
RU2741426C1 |
| PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | 2014 |
|
RU2728778C2 |
| AGENT FOR PREVENTING AND TREATING UROLITHIASIS | 2015 |
|
RU2580282C1 |
| NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | 2014 |
|
RU2675364C2 |
| NHE3 BINDING COMPOUNDS AND METHODS FOR PHOSPHATE TRANSPORT INHIBITION | 2014 |
|
RU2786149C2 |
| PHOSPHATE ADSORBENT | 2010 |
|
RU2527682C2 |
| COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | 2014 |
|
RU2771808C2 |
| APPLICATION OF METHYL NALTREXONE FOR TREATING IRRITABLE COLON SYNDROME | 2004 |
|
RU2373936C2 |
| METHOD OF TREATING GEFITINIB-RESISTANT CANCER | 2006 |
|
RU2405566C9 |
